Skip to main content

  • Thin-Strut Synergy Stent Noninferior to BioMatrix NeoFlex Stent at 5 Years – SORT OUT VIII Trial

    The thin-strut everolimus-eluting stent (Synergy, EES) was found to be non-inferior in treating routine clinical care patients when compared to the biolimus-eluting stent (BioMatrix NeoFlex, BES), according to 5-year follow-up data from the SORT OUT VIII trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details